The impact of diagnosis of hepatitis C virus on quality of life
Lisa Forman, Steven Kawut, Ilene Rosen, Grace Pien, Hillary Bogner – 30 December 2003
Lisa Forman, Steven Kawut, Ilene Rosen, Grace Pien, Hillary Bogner – 30 December 2003
Kiran Bambha, W. Ray Kim – 30 December 2003
Alan S. Perelson, Ruy M. Ribeiro, Jennifer E. Layden‐Almer, Thomas J. Layden – 30 December 2003
Robert H. Costa, Vladimir V. Kalinichenko, Ai‐Xuan L. Holterman, Xinhe Wang – 30 December 2003
Gerond Lake‐Bakaar, Simon D. W. Frost – 30 December 2003
M. George DeBusk, Yoogoo Kang, Cataldo Doria, Victor J. Navarro, Ignazio R. Marino, Howard R. Doyle – 30 December 2003
Carlos G. Fasola, Goran B. Klintmalm – 30 December 2003
George N. Tzimas, Jeffrey S.T. Barkun, Peter Metrakos, Jean I. Tchervenkov – 30 December 2003
Hugo E. Vargas – 30 December 2003 – In many transplant centres lamivudine is an important component of prophylaxis against, and treatment of, hepatitis B virus (HBV) graft infection. Drug resistant HBV species with specific polymerase mutations may emerge during lamivudine treatment. Aims: To examine the clinical consequences of graft infection by lamivudine resistant virus. Methods: The clinical course of four liver transplant patients who developed graft infection with lamivudine resistant virus was reviewed.
Steffen R. Mitzner, Jan Stange, Sebastian Klammt, Teut Risler, Christiane M. Erley, Brigitte D. Bader, Elke D. Berger, Werner Lauchart, Piotr Peszynski, Jens Freytag, Heiko Hickstein, Jan Loock, Johannes‐Mathias Löhr, Stefan Liebe, Jörg Emmrich, Gero Korten, Reinhard Schmidt – 30 December 2003 – In hepatorenal syndrome (HRS), renal insufficiency is often progressive, and the prognosis is extremely poor under standard medical therapy.